Table 3.
Studies assessing the effect of TNF inhibitors on rheumatologic parameters and cytokine levels.
| Authors | Subjects | Assesment | DAS28 | Serum CRP levels | Serum TNF-α levels | GCF TNF-α levels |
|---|---|---|---|---|---|---|
| Mayer et al. (24) | RA+ (n = 10) compared to RA without anti-TNF-α (n = 10) | 1 moment(1 calibrated examiner) | NS p > 0.05 |
– | – | ↓(sig.) p = 0.04 |
| Mayer et al. (25) | RA+ compared to AI (RA, PA and SSc) | 1 moment(2 calibrated examiners) | – | – | – | ↓(sig.) p = 0.002 |
| Schiefelbein et al. (26) | RA with PD on anti-TNF-α for >12 months (n = 13) versus non RA with PD (n = 13) | 1 moment(1 calibrated examiner) | – | NS p = 0.310 |
– | – |
| Üstün et al. (27) | RA patients with PD (n = 10) | BL + after 30 days(1 examiner) | ↓(sig.) p = 0.001 | ↓(sig.) p = 0.02 | – | – |
| Ortiz et al. (28) | RA patients on PDT and anti-TNF-α (n = 10) | BL + after 6 weeks(1 calibrated examiner) | ↓(sig.) p < 0.005 | – | ↓(sig.) p < 0.001 | – |
| RA patients on anti-TNF-α (n = 10) | BL + after 6 weeks(1 calibrated examiner) | NS p > 0.005 |
– | NS p = 0.2 |
– | |
| Kadkhoda et al. (29) | RA patients (n = 36) | BL + after 6 weeks | – | – | – | ↓(sig.) p = 0.04 |
| Kobayashi et al. (30) | Patients with RA (n = 20) | BL + after 3 months(2 calibrated examiners) | ↓(sig.) p < 0.001 | ↓(sig.) p < 0.001 | ↓(sig.) p < 0.001 | – |
| Kobayashi et al. (31) | RA patients treatment with anti-TNF-α (n = 40) | BL + after 3 and 6 months(1 examiner calibrated + masked) | ↓(sig.) p < 0.017 | ↓(sig.) p < 0.017 | ↓(sig.) p < 0.017 | – |
| Savioli et al. (32) | RA patients with PD (n = 8) | BL + after 6 months(1 blinded examiner) | NS p = 0.11 |
NS p = 0.55 |
– | – |
| RA patients without PD (n = 10) | BL + after 6 months(1 blinded examiner) | ↓(sig.) p = 0.04 | ↓(sig.) p = 0.01 | – | – | |
| Fabri et al. (33) | AS patients and PD (n = 7) | BL and + 6 months(1 blinded examiner) | – | ↓(sig.) p = 0.03 | – | – |
| Patients with RA and PD (n = 7) | BL and + 6 months(1 blinded examiner) | ↓(sig.) p = 0.01 | ↓(sig.) p = 0.008 | – | – | |
| Ancuta et al. (34) | RA patients (n = 96) RA patients (n = 96) | BL and after 6 months | ↓(sig.) p < 0.05 |
↓(sig.) p < 0.05 | ↓(sig.) p < 0.05 | – |
| Iordache et al. (35) | AS patients (n = 86) | BL and after 6 months | ↓(sig.) *p < 0.05 | ↓(sig.) p < 0.05 | – | – |
| Pers et al. (36) | RA patients with PD (n = 9) | BL + after 9 months(1 blinded examiner) | – | – | – | – |
RA, rheumatoid arthritis patients; RA+, rheumatoid arthritis with anti-TNF-α therapy; AS, ankylosing spondylitis; AI, Autoimmune disease; PA, psoriatic arthritis, SSc, systemic sclerosis; PDT, periodontal treatment; PD, periodontitis; DAS28, disease activity score; CRP, C-creative protein; sig., statistically significant; NS, not statistically significant *ASDAS28 ankylosing spondylitis disease activity score.
Green: significant improvement, Red: significant worsening.